Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 75   

Articles published

ARNA 4.36 -0.09 (-2.02%)
price chart
Could Arena Pharmaceuticals Inc. Be Running Out of Money?
With Wall Street not expecting the company to be profitable on annual basis until 2017, it's worth digging beyond the surface to discover whether or not Arena Pharmaceuticals could be running out of money. Today we'll do just that, as well as look at ...
Related articles »  
Will Arena Pharma (ARNA) Q3 Loss Be Wider than Expected?
Arena Pharmaceuticals, Inc. (ARNA - Snapshot Report) is scheduled to report its third-quarter 2014 results before the opening bell on Nov 3. Last quarter, the company had posted a negative earnings surprise of 9.09%.
Related articles »  
Eisai Earnings Give Arena Investors Insights (ARNA)
Additional revenue for Arena can come from manufacturing services, other Eisai collaborative revenue, and the sale of Taigen stock that the company still holds. I anticipate that manufacturing revenue will be between $500,000 and $700,000. I anticipate ...
Stocks Worth Adding To Your Watchlist: Alpha Pro Tech, Ltd. (APT), Arena ...  Markets Emerging
Lorcaserin Data to be Presented at The Obesity Society's Annual ...  MarketWatch
Related articles »  
Trader's Buzz: Unilife Corporation (UNIS), Arena Pharmaceuticals (ARNA ...
ARNA shares recently gained $0.01 to $4.36. The stock is down more than 2.22% year-over-year and has lost roughly 24.79% year-to-date.
Arena Pharmaceuticals Inc (NASDAQ:ARNA) Weekly Performance Is Improving
Arena Pharmaceuticals Inc (NASDAQ:ARNA) has a one year low of $3.26 and a one year high of $7.97. Arena Pharmaceuticals Inc (NASDAQ:ARNA) opened with a price of 4.26 and hit a high of 4.46 with a low of 4.15 on the last trading day.. Arena ...
Arena Pharmaceuticals Earns Market Perform Rating from BMO Capital Markets ...  Ticker Report
Arena Pharmaceuticals (ARNA) to Release Quarterly Earnings on Monday  WKRB News
Related articles »  
Pharma Stocks to Watch: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Monday said data from phase 3 clinical trials of its obesity drug BELVIQ (lorcaserin HCl) will be presented at the American College of Clinical Pharmacy meeting taking place through Wednesday of this week.
Related articles »  
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA ...
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and ...
Related articles »  
Watch List -Nanosphere, Inc. (NSPH), Arena Pharmaceuticals, Inc. (NASDAQ ...
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)publicized top-line results of a pilot study to assess the safety of lorcaserin HCl, a serotonin 2C receptor agonist, when coadministered with phentermine HCl.
Belviq Sales Flat - Model Your Expectations (ARNA)
Sales of Arena Pharmaceuticals' (NASDAQ:ARNA) Belviq were essentially flat this week vs. last week, according to industry tracker IMS Health (NYSE:IMS).
Related articles »  
Arena Pharmaceuticals's Market Perform Rating Reiterated at BMO Capital ...
Arena Pharmaceuticals, Inc. logo BMO Capital Markets reiterated their market perform rating on shares of Arena Pharmaceuticals (NASDAQ:ARNA) in a research note released on Thursday morning.
Arena Pharmaceuticals Receives "Market Perform" Rating from BMO ...  Mideast Time
News Recap: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), Achillion ...  Market News Call
Related articles »